Tumor cells
View article: Supplementary Figures 1-6 from Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors
Supplementary Figures 1-6 from Comparative Tumor Microenvironment Analysis of Primary and Recurrent Ovarian Granulosa Cell Tumors Open
S1. Heatmap of unsupervised hierarchical clustering of the top 1000 most variable genes.S2. Violin plots showing the expression levels of genes previously identified as differentially expressed genes between primary and recurrent tumors in…
View article: Figure S.1 from ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies
Figure S.1 from ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies Open
A prostate tumor cell line (PC3M-A2/beta 2M) was inoculated subcutaneously in the right flank of CD34-humanized NSG mice. Mice were treated intravenously at indicated time points with either vehicle or with an ABBV-184 precursor molecule, …
View article: Supplementary Fig.S2 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Supplementary Fig.S2 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors Open
Supplementary Fig.S2 shows PTK7 expression in normal human tissues surveyed by mAb13
View article: Supplementary Figure 2 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Supplementary Figure 2 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma Open
Loss of tumor-derived CCL5 reduces tumor cell proliferation in TE-1 cells.
View article: Supplementary Figure 7 from Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation
Supplementary Figure 7 from Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation Open
Supplementary Figure 7 shows that the transduction of miR-143-3p did not affect tumor growth in a murine model of ovarian cancer.
View article: Supplementary Figure 4 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Supplementary Figure 4 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma Open
Targeted CCR5 inhibition replicates CCL5 loss with reduced tumor cell proliferation in vitro and in vivo.
View article: Table S1 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Table S1 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures Open
Supplementary Table 1 drug concentrations
View article: Supplementary Data Figure S1 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Supplementary Data Figure S1 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures Open
Figure S1
View article: Supplementary Fig.S6 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Supplementary Fig.S6 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors Open
Supplementary Fig.S6 shows PTK7 is an actionable target in small cell lung cancer
View article: Figure S2 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Figure S2 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors Open
Example gating strategy for tumor samples in order to acquire CD163 and LILRB2 + cells
View article: Supplementary Fig S2 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis
Supplementary Fig S2 from Hypertension Promotes the Proliferation and Migration of ccRCC Cells by Downregulation of TIMP3 in Tumor Endothelial Cells through the miR-21–5p/TGFBR2/P38/EGR1 Axis Open
Supplementary Figure 2 shows the efficiency of endothelial cell depletion in immunomagnetic cell separation, and TIMP3-overexpression in HUVECs suppressed the growth of 786O cancer cells implanted in the subcutaneous tissue of nude mice.
View article: Supplementary Figures 1 and 2 from Exosomal lincROR Promotes Docetaxel Resistance in Prostate Cancer through a β-catenin/HIF1α Positive Feedback Loop
Supplementary Figures 1 and 2 from Exosomal lincROR Promotes Docetaxel Resistance in Prostate Cancer through a β-catenin/HIF1α Positive Feedback Loop Open
S1. A. CCK-8 assay was used to detect the cytotoxicity of DTX in DTX-resistant PCa cells (PC3/DR and DU145/DR) and their parental sensitive cells (PC3 and DU145). B. The list of hypoxia-related lncRNAs from Pubmed and the top 80 upregulate…
View article: Figure S8 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors
Figure S8 from Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors Open
Changes in gene expression by JTX-8064 in both macrophages and dendritic cells 6 days on treatment during differentiation
View article: Figure S1 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
Figure S1 from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103 Open
Immunofluorescence of 33 human lung tumor samples on a microarray probed with GT103.
View article: Supplementary Figure S1 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Supplementary Figure S1 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells Open
Supplementary Figure S1 shows data describing the characterization of the interaction between SLC1A5 and CAIX in cancer cells.
View article: Supplementary Fig. S5 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S5 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis Open
IVMT-Rx-3 inhibited MDA-9/Src signaling cascade
View article: Supplementary Figures 1-5 from Identification of a First-in-Class Small-Molecule Inhibitor of the EIF4E-RBM38 Complex That Enhances Wild-type TP53 Protein Translation for Tumor Growth Suppression
Supplementary Figures 1-5 from Identification of a First-in-Class Small-Molecule Inhibitor of the EIF4E-RBM38 Complex That Enhances Wild-type TP53 Protein Translation for Tumor Growth Suppression Open
Supplementary Figures 1-5
View article: Supplementary Tables from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Supplementary Tables from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models Open
Tables S1-S4
View article: Supplementary Materials and Methods SM1 from Bcl-xL Is a Key Mediator of Apoptosis Following KRAS<sup>G12C</sup> Inhibition in <i>KRAS<sup>G12C</sup></i>-mutant Colorectal Cancer
Supplementary Materials and Methods SM1 from Bcl-xL Is a Key Mediator of Apoptosis Following KRAS<sup>G12C</sup> Inhibition in <i>KRAS<sup>G12C</sup></i>-mutant Colorectal Cancer Open
Supplementary materials and methods
View article: Supplementary Figure S4 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Supplementary Figure S4 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells Open
Supplementary Figure S4 shows that the combined loss of CAIX activity and the GSH synthesis axis of Gln metabolism increases cytotoxicity of hypoxic cancer cells.
View article: Supplementary Fig. S7 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis
Supplementary Fig. S7 from Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis Open
IVMT-Rx-3 suppressed tumor cell derived pro-inflammatory cytokines expression.
View article: Table S4 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Table S4 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures Open
Supplementary Table 4 LOBICO PDXC % sens vs insens
View article: Supplementary Figure S3 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells
Supplementary Figure S3 from A Carbonic Anhydrase IX/SLC1A5 Axis Regulates Glutamine Metabolism Dependent Ferroptosis in Hypoxic Tumor Cells Open
Supplementary Figure S3 shows heatmaps showing the drug combination responses for cytotoxicity of cancer cells in hypoxia induced by SLC-0111 in combination with inhibition of Gln metabolism.
View article: Figure S3 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP
Figure S3 from TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP Open
Figure S3A: Tumor photograph in the nude mouse subcutaneous xenograft model by implanting TRIM50 overexpressing (TRIM50) versus control empty vector (EV) MKN45 cells (n = 6 mice per group). Scale bar: 1 cm Figure S3B: MKN74 cells were tran…
View article: Supplementary Figure S4 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer
Supplementary Figure S4 from Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer Open
Baseline differences in tumor progression and histopathology of G12D versus G12C KP GEM models
View article: Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy Open
Analysis of B16F10 tumor growth in mice treated with OATD-02 in all individuals subjected to the study.
View article: Supplementary Figures from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Supplementary Figures from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models Open
Figures S1-S9
View article: Supplementary Fig.S8 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Supplementary Fig.S8 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors Open
Supplementary Fig.S8 shows MTX-13 prevents metastasis in vivo in an orthotopic colon cancer xenograft model
View article: Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy Open
The immunosuppressive character of ARG1 and ARG2 in the tumor microenvironment (TME)
View article: Supplementary Table S3 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Supplementary Table S3 from Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication Open
Data for Figure 4B